Hepalair 150mg/100mg Tablet is a combination pharmaceutical formulation containing L-Ornithine L-Aspartate (150mg) and Pancreatin (100mg), designed to support hepatic function and improve digestive enzyme activity. L-Ornithine L-Aspartate is an amino acid derivative that facilitates ammonia detoxification by enhancing the urea cycle, thereby reducing blood ammonia levels commonly elevated in hepatic encephalopathy and liver dysfunction. Pancreatin, a mixture of digestive enzymes including amylase, lipase, and protease, aids in the breakdown of carbohydrates, fats, and proteins, improving nutrient absorption in patients with pancreatic insufficiency or digestive disorders. Hepalair is indicated for adjunctive therapy in chronic liver diseases such as cirrhosis and hepatitis, where compromised liver function leads to metabolic imbalances and impaired digestion. The tablet form ensures convenient oral administration, promoting patient compliance. Hepalair should be used under medical supervision, with dosage adjusted according to clinical response and liver function status. Contraindications include hypersensitivity to any component and acute pancreatitis. Common adverse effects are generally mild and may include gastrointestinal discomfort. Hepalair offers a dual mechanism approach by simultaneously addressing hepatic detoxification and digestive enzyme supplementation, contributing to improved metabolic homeostasis and patient quality of life.